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ABSTRACT
Gfi1b is a 37 kDa transcriptional repressor with six
zinc-finger domains that is differentially expressed
during hemato- and lymphopoiesis. We show here
that transcription from the Gfi1b gene locus is
silenced in the spleen but not in the bone marrow of
transgenic mice that constitutively express Gfi1b
under the control of the pan-hematopoietic vav
promoter. Sequence analysis of the Gfi1b promoter
showed the presence of potential Gfi1/Gfi1b-binding
sites close to the mRNA start site. The expression
of reporter gene constructs containing the Gfi1b
core promoter appended to the luciferase gene
were strongly repressed in the presence of exo-
genous Gfi1b. Moreover, analysis of combinatorial
mutant mice that carry the vav-Gfi1b trans-
gene and a green fluorescent protein-tagged Gfi1
gene locus demonstrated that the Gfi1 gene can
be repressed by Gfi1b. Direct binding of Gfi1b
and Gfi1 to the potential binding sites in the Gfi1b
promoter could be demonstrated by gel-shift ana-
lyses in vitro. Chromatin-immunoprecipitation exp-
eriments showed that both the Gfi1b and the Gfi1
promoter are indeed occupied by Gfi1b in vivo.
Hence, we conclude from our data that Gfi1b can
auto-repress its own expression, but, in addition,
is also able to cross-repress expression of the Gfi1
gene most likely in a cell type specific manner.
INTRODUCTION
Gﬁ1b and Gﬁ1 are small nuclear proteins with a theoretical
molecular weight of 37 and 47 kDa, respectively [for review
see (1,2)]. Both can repress RNA Pol II dependent
transcription upon direct binding to cognate sites in target
gene promoters. DNA binding to these sites which contain
an AATC core sequence is mediated by six C2H2 type zinc
ﬁngers located at the C-terminus of both proteins. At the
N-terminus, a 20 amino acid SNAG domain that is conserved
between Gﬁ1 proteins of all mammalian species is indispens-
able for transcriptional repression (3,4). Within the SNAG
domain and the zinc-ﬁnger motifs, amino acid sequences in
Gﬁ1 and Gﬁ1b are almost identical. However, the area sep-
arating both the domains is not conserved and does not harbor
any known domain homology. Hence, the function of this part
of the proteins remains obscure but a role as a protein–protein
interaction domain is conceivable.
Gﬁ1 and Gﬁ1b are both differentially expressed during
lympho-andhematopoiesis(1,2).Gﬁ1ismostprominentlypre-
sent in the early stages of T-cell development, ceases in
mature, resting CD4
+ or CD8
+ peripheral T-cells, but can
be steeply re-induced upon antigenic stimulation (5–8). In
contrast, Gﬁ1b appears to be largely absent from T-cells
save for a reported expression in the earliest DN3 subset of
the CD4
  CD8
  thymocyte population (9). Similarly, B-cell
precursors in bone marrow and spleen show constitutive
expression of Gﬁ1 but mature, resting B-cells lack Gﬁ1 and
re-express it only after stimulation (8). In the myeloid lineage,
granulocytes show high levels of Gﬁ1 expression whereas
Gﬁ1b is completely absent and vice versa. Gﬁ1b is highest
in erythroid precursors and megakaryocytes where Gﬁ1 can
barely be detected (10,11). Outside the hematopoietic system,
Gﬁ1 is expressed in precursors of sensory neurons, the retina,
speciﬁc cells of the lung and in the CNS (12). Whether Gﬁ1b
shows signiﬁcant expression in these or other organs has not
been thoroughly investigated.
Although both Gﬁ1 and Gﬁ1b are highly similar, it remains
to be shown to what extent they are redundant or exert unique
and speciﬁc functions. Gene knock-out studies have shown
that loss of Gﬁ1 affects pre-T-cell differentiation, develop-
ment of granulocytes, integrity of inner ear hair cells, and
proliferation and self-renewal of hematopoietic stem cells
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doi:10.1093/nar/gki243(7,10,12–15). In contrast, the deletion of Gﬁ1b leaves the
myeloid lineage and hematopoietic stem cells undisturbed,
but has drastic effects on the development of erythroid cells
and megakaryocytes (11). Since Gﬁ1b null mice die at mid
gestation, the consequences of Gﬁ1b deletion on other cell
types and organs could not be investigated.
The promoter of the Gﬁ1 gene contains a number of bona
ﬁde Gﬁ1-binding sites with the typical AATC core sequence.
Two independent studies have shown that Gﬁ1 expression is
regulatedbyafeedback loopthroughGﬁ1itself(8,16).Results
from chromatin immunoprecipitation (ChIP) and reporter
gene assays suggest that Gﬁ1 binds to sequences within its
own promoter and can repress its own transcription (8,16).
Interestingly, this auto-regulation appears to be conﬁned to
T-cells and is absent in myeloid cells (16), but the reason for
this cell type speciﬁc auto-regulation is entirely unknown.
Since the same DNA-binding motifs can be used by Gﬁ1
and Gﬁ1b, a cross-regulation of the Gﬁ1 gene by Gﬁ1b is
possible, and evidence supporting such a regulatory mechan-
ism has recently been published (16). By using a transgenic
mouse model and several cell-based systems, we show that the
Gﬁ1b gene, similar to the Gﬁ1 gene, underlies auto-regulation
and that a direct transcriptional repression of the Gﬁ1b pro-
moter by Gﬁ1b occurs in vivo. Furthermore, we conﬁrm that
Gﬁ1 expression can be repressed in vivo by Gﬁ1b using
a Gﬁ1:GFP knock-in mouse mutant and animals that express
Gﬁ1b as a transgene and, ﬁnally, we demonstrate that Gﬁ1 can
repress transcription from the Gﬁ1b reporter. The data in this
paper complete a picture in which, at least in lymphoid cells,
both Gﬁ1 and Gﬁ1b are not only able to repress their own
expression, i.e. under auto-regulatory control, but can also
cross-regulate each other by mutually silencing their
promoters.
MATERIALS AND METHODS
Generation of vav-Gfi1b transgenic mice
ThetransgeneconstructwasgeneratedbyinsertingthemGﬁ1b
cDNA in a pIC19H-based plasmid containing the vav pro-
moter and enhancer which was kindly provided by J. Adams
(17). In order to measure the Gﬁ1b expression elicited by the
transgene, a HindIII restriction site was removed from the
inserted Gﬁ1b cDNAs by silent mutation. Transgenic mice
were generated by the standard microinjection method. Mice
were housed at the IFZ animal facility, University of Essen
Medical School, in single ventilated cages under speciﬁc
pathogen-free conditions according to German animal legisla-
tion. Mice that were used for analyses were healthy 4- to
6-week-old animals from a several generation backcross
with C57BL/6 animals.
Mapping of DNase I hypersensitive sites
A single cell suspension from wt spleen was prepared, washed
in ice cold phosphate-buffered saline and resuspended in 15 ml
homogenization buffer (0.3 M sucrose, 60 mM KCl, 15 mM
NaCl, 15 mM Tris, pH 7.5, 5 mM MgCl2, 0.5 mM EGTA and
0.2 mM AEBSF) per 10
7 cells. The nuclei were isolated by the
additionof15mlhomogenizationbufferplus1%NP40per10
7
cells, incubation for 5 min on ice and centrifugation at 1500 g.
The nuclei were then washed 2-fold with homogenization
buffer without NP40 and resuspended in 2 ml of DNase buffer
(60 mMKCl,15mM NaCl, 15mM Tris,pH7.5,5mMMgCl2,
0.2 mM EGTA and 0.2 mM AEBSF). Three hundred micro-
liter each of the nuclei suspension were incubated for 15 min
on ice with 0, 80, 160, 240, 480 or 720 U of DNase I (Grade II,
Roche).Thereactionwasstoppedbyadding1.7mlproteinase-
K digestion buffer (60 mM Tris, pH 8.0, 25 mM EDTA, 1.2%
SDS and 400 mg proteinase-K) to each vial and incubating
at 37 C for 16 h. Nuclear DNA was prepared by phenol-
extraction and ethanol-precipitation. The DNA was resolved
in 400 ml TE (10 mM Tris, pH 7.5, 1 mM EDTA) and incub-
ated with 20 mg RNase-A for 30 min at 37 C. The DNA was
digested with 30 U of SmaI for 6 h at 37 C, ethanol-
precipitated, redissolved in 25 ml TE, separated on a 0.8%
agarose-gel, transferred to a solid support and hybridized
using a PCR generated 296 bp probe directly downstream
ofthe SmaI site. The result was visualizedby autoradiography.
Probe-primers: SmaUS, cctgggatccttcagtggcagag; and
SmaLS, gtcctggaactccctctatagaac.
Primer extension analysis
This section deals with primer extension on bone marrow and
spleen cells from wt and Gﬁ1b transgenic mice. Total RNA
was prepared from each tissue (bone marrow BM, spleen SP)
with Peq-Gold (PEQLAB) according to the manufacturer’s
protocol. Yeast t-RNA (Y) was used as a negative control.
The primer for the primer extension analysis, 50-gactgctc-
tcggctcggtcaac-30, was synthesized to hybridize the sense
strand from nucleotides  34 to  13 in the ﬁrst exon of the
Gﬁ1b gene. The synthetic primer was labeled at its 50 end with
32P-ATP using T4 polynucleotide kinase and hybridized to
1 mg total RNA in reverse transcriptase buffer at 58 C.
After cooling to 43 C, the primer was extended with 200 U
of SuperScript II RNase H–reverse transcriptase (Invitrogen)
using1mMeachofthefourdeoxynucleotides.After1hat37 C,
the reaction was neutralized and the DNA was collected. The
reaction products were analyzed on a 7 M urea–6% polyac-
rylamidegeltodeterminethesizeoftheextended product.The
gel was exposed to an autoradiography ﬁlm (Kodak BioMax).
Gel-shift analysis
The Myc-tagged Gﬁ1 and Gﬁ1b proteins were produced with
the TNT(TM) Rabbit Reticulocyte Lysate System (Promega).
Unprogramed lysate was used as control.
One micorliter of lysate was incubated for 20 min at room
temperature with 7 ml of gel-shift buffer (40 mM KCl, 30 mM
HEPES-KOH, pH 7.6, 1 mM MgCl2, 5% Glycerol, 15%
Ficoll, 5 mM DTT, 0.25 mg/ml poly(dI dC) with or without
1 pM (20 000 Cz-c.p.m.) 32P-labeled double-stranded oligo-
nucleotides. When indicated for test of speciﬁcity, 50 pM
unlabeled target or non-target oligo was added to compete
for binding with the protein of interest. After preincubation
for 20 min, anti-Myc antibody was added to the protein:DNA
complex for 10 min to further retard its mobility (supershift)
during electrophoresis. Protein:DNA complexes were separ-
ated using a native acrylamide gel (4% PAA, 0.5· TBE) and
visualized by autoradiography. Oligos: Gﬁ1b-shift-US1, gatc-
cacaaataatcagatgaaaacaggaggg; Gﬁ1b-shift-LS, gatcccctccga-
ttttcaatctgattatttgtg; Ideal US, gatcaaaataaatcacagcat; Ideal
988 Nucleic Acids Research, 2005, Vol. 33, No. 3LS, gatcatgctgtgatttatttt; CRE US, gatccttggctgacgtcagagaga-
gct; CRE LS, ctctctgacgtcagccaag; SAT-A US, tatggcgaggaa-
aactgaaaaaggtggaaaatttagaaatgt; SAT-A LS, acatttctaaattttcc-
acctttttcagttttcctcgccata; SAT-B US, aaactgaaaatcatggaaaat-
gagaaacat; SAT-B LS, atgtttctcattttccatgattttcagttt; IKAROS
US, tgacagggaatacacattcccaaaagc; and IKAROS LS, gcttttgg-
gaatgtgtattccctgtca.
ChIP
ChIP procedures were performed as described previously (8).
Primers used for DNA ampliﬁcation of the Gﬁ1b locus were:
Gﬁ1b-ChIP-US1, tctaaagcaaggatgagggactgta; and Gﬁ1b-
ChIP-LS1, gtgtcaaaatctggcggctgcagc. After 32–35 cycles of
ampliﬁcation, PCR products were run on 1.5% agarose gel and
analyzed by ethidium bromide staining. Primers to amplify
sequences of the Gﬁ1 locus were as described previously (8).
Transient transfection and reporter gene assay
To generate Gﬁ1b full-length and deletion construct expres-
sion plasmids, the Gﬁ1b cDNA was PCR ampliﬁed, cloned
using the TOPO-PCR cloning kit (Invitrogen) and PCR-
products were sequenced and subcloned into the pCDNA3.1
(Invitrogen) mammalian expression plasmid. Primers used for
ampliﬁcation were: Full1BUS, gaattccgcgatgccacggtcctttcta-
gtg; dSnagUS, gaattccgcgatggcacagggtgatgagctg; Full1BLS,
tcaggatcccttgagattgtgttgactctc; dZNF6LS, tcaggatcccttgaag-
cctgtgtgcttgcg; and dZNF5LS, tcaggatcccttctcacctgtgtggatgta.
For the VP16 activation domain (AD) fusion proteins, ﬁrst a
HindIII, EcoRI VP16 AD fragment from the pVP16 yeast
expression plasmid was cloned into pCDNA3. Then the poly-
linker was mutated by the insertion of an adapter into the
BamHI/XbaI sites to generate in-frame cloning sites for
Gﬁ1b, followed by EcoRI/BamHI cloning of the Gﬁ1b inserts
from the pCDNA3-Gﬁ1b clones described above into the
pCDNA-VP16 vector. Primers for the generation of the
adapter were: VP16poly3US, gatctcgaattcagaagcttctcgagctgg-
atcctaagtga; and VP16poly3LS, ctagtcacttaggatccagctcgagaa-
gcttctgaattcga. Luciferase reporter plasmids were generated
by the insertion of PCR-ampliﬁed mouse genomic sequences
covering the regions from  798 to +31 (Gﬁ1b-long-promoter)
or from  511 to +31 (Gﬁ1b-short-promoter) into the pGL3-
basic vector (Promega). Primers for the ampliﬁcation of
the promoter sequences were: 1Bprom9050US, ctgc-
gctggcctgggtacccag; and 1Bprom9896LS, ggcagatctgactg-
ctctcggctcggtcaacg. As a control, an oligo covering the
Gﬁ1/Gﬁ1b-binding site in the Gﬁ1b promoter was inserted
into the BglII site in the polylinker of the pGL3-promoter
vector (Promega). Primers for the generation of the binding
site were Gﬁ1b-shift-US1 and Gﬁ1b-shift-LS1 as described
above. In 12 well plates, 5 · 10
4 NIH-3T3 cells per well were
seeded and transfected 24 h later with 1 mg luciferase con-
struct, and the indicated amount of a cytomegalovirus-
driven Gﬁ1b Myc tagged expression plasmid using Rotifect
according to the manufacturer’s instructions. The amount of
DNA was kept constant in each transfection by adding empty
vector where necessary. All DNA constructs were conﬁrmed
by sequencing. After 48 h, cells were lysed at 4 Ci n2 5m M
Tris (pH 7.8), 2 mM 1,2-diaminocyclohexane-N,N,N0,
N0-tetraacetic acid, 10% glycerol, 1% Triton X-100, 2 mM
DTT, 0.3 mM phenylmethlysulfonyl ﬂuoride and 2 mg/ml
aprotinin. The luciferase activity was measured by lumino-
metry after diluting the lysate 1:3 or 1:5 in 25 mM glycyl
glycine, 15 mM MgSO4,1 5m MK 2HPO4, 4 mM EGTA,
40 mM ATP, 40 mM DTT and 0.3 mg/ml of luciferin. Expres-
sion of Gﬁ1b or Gﬁ1b mutants was conﬁrmed by immunoblot-
ting using an afﬁnity puriﬁed Gﬁ1b-speciﬁc rabbit polyclonal
antibody.
Retrovirus production and generation of transformed
pre-B lines expressing p210 BCR-ABL
Plasmid constructs, pSRaMSCV-p210-tkneo and MSCV-
GFP-IRESp210 (a gift from Dr O. N. Witte), were used to
produce helper-free retroviral stocks by transient over expres-
sion in 293T cells as described previously (18). For estimation
of the viral titers, viral stocks were serially diluted and used
to infect 3T3 indicator cell lines. Viral titers were determined
by counting green ﬂuorescent protein (GFP) positive cells
(MSCV-GFP-IRESp210) or by counting G418-resistant col-
oniesafterselection(pSRaMSCV-p210-tkneo).Routinely,we
obtained titers of >5 · 10
5/ml. For generation of transformed
pre-B lines, fresh bone marrow from tibias and femurs of 4- to
8-week-old C56Bl/6 mice (wild-type and Gﬁ1b transgene)
was infected with retroviral stocks of different BCR-Abl con-
structs and plated at a density of 5 · 10
6 per 6 cm dish as
described previously (18). All pre-B lines were fed twice a
week and analyzed after they became stroma independent.
RESULTS
Auto-regulation of the Gfi1b gene in vivo
To gain more insight into the molecular function of Gﬁ1b, we
have generated transgenic mice in which a constitutive expres-
sion of Gﬁ1b was targeted to all hematopoietic cells by the
vav promoter enhancer element, which has been previously
described to be effective in directing pan-hematopoietic
expression [Figure 1a and (17)]. The animals harbor a
Gﬁ1b cDNA with a disrupted HindIII restriction site to facil-
itate the distinction between endogenous (wt) and transgenic
(tg) Gﬁ1b transcripts by RT–PCR (Figure 1a). High-level
expression of the Gﬁ1b transgene both on RNA and protein
level was reached in bone marrow, thymus and spleen
(Figure 1b and c) of two different, independently generated
lines of mice (Line 1 and 7). Save for a slightly higher number
of B220
+ cells in bone marrow, spleen and peripheral blood,
ﬂowcytometric analysis did not reveal major alterations of
lymphoid or myeloid subsets in spleen and bone marrow or
the pre-T-cell subsets in the thymus of 4- to 8-week-old vav-
Gﬁ1b transgenic mice compared with age-matched littermates
(data not shown). Surprisingly, however, endogenous (wt)
Gﬁ1b transcripts were absent in spleen, but not in bone
marrow of vav Gﬁ1b transgenic mice (Figure 1d). In thymus,
endogenous expression of Gﬁ1b was not detected under the
conditions employed here and the only measurable Gﬁ1b-
speciﬁc transcripts originated from the Gﬁ1b transgene
(Figure 1b–d).
To test whether the absence of endogenous Gﬁ1b transcripts
inspleen isduetoa bonaﬁde auto-regulationofthe Gﬁ1bgene
in B-cells or due to different expression levels in wt or vav-
Gﬁ1b transgenic mice or due to different subpopulations of
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Gﬁ1b transgenic mice by infecting bone marrow cells with
retroviral vectors (MSCV or pSRalpha type) expressing the
BCR/Abl fusion protein. Four B220
+ B-cell lines, two from
transgenic bone marrow and two from wt bone marrow were
generated with each retrovirus. The cell lines derived from
vav-Gﬁ1b transgenic mice expressed a signiﬁcantly higher
amount of Gﬁ1b protein than cell lines from wt bone marrow
(Figure 1e). When RNA from these cell lines was analyzed by
RT–PCR, no endogenous Gﬁ1b transcript could be detected in
cells derived from the vav-Gﬁ1b transgenic mice (Figure 1f),
suggesting a direct and complete auto-regulation of the endo-
genous Gﬁ1b gene by Gﬁ1b itself in B-cells.
The sequence of the Gfi1b promoter is partially
conserved and harbors several Gfi1-binding sites
Primer extension experiments with RNA from wt spleen or
bone marrow cells and a primer located within exon 1 of Gﬁ1b
yielded two major fragments of 60 and  490 bp in size and a
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Figure 1. Generation and analysis of vav-Gfi1b transgenic mice. (a) Schematic representation of the vav-Gfi1b construct used to generate transgenic mice. The
Gfi1b cDNA was placed under the control of the enhancer and promoter elements of the vav gene. To terminate transcription, a SV 40 polyadenylation signal was
inserted at the end of the Gfi1b cDNA. (b) Expression of the vav-Gfi1b transgene was detected by RT–PCR in bone marrow (BM), spleen (Sp) and thymus (Th) of
twomouselines(1and7).Inboththelines,higherlevelsofmRNAwereapparentinallthethreeorgansofvav-Gfi1btransgenicmice(tg)thaninwild-typeanimals
(wt).EndogenousGfi1bmRNAwaspresentinbonemarrowandspleenofwtmicebutwasabsentinthymusandliver(Li)fromwtmice.Thesignalinthetransgenic
liverfromline7is veryprobablyduetothecontaminationwithbloodcells.(c) SignificantlyhigherlevelsofGfi1bproteinweredetectedbyimmunoblot inextracts
from spleen (Sp) and thymus (Th) from vav-Gfi1b transgenic mice (tg) than from wild-type animals (wt). (d) HindIII digestion of RT–PCR products distinguishes
between endogenous (wt) and transgenic Gfi1b expression. Endogenous Gfi1b expression is lost in spleen but not in bone marrow of vav-Gfi1b transgenic mice.
(e)DetectionofGfi1bproteinexpressionlevelsbyimmunoblotincelllinesestablishedafterinfectionofbonemarrowfromwtorvav-Gfi1btransgenicmice(tg)with
a pSRa vector driving the expression of the p210 BCR/Abl fusion protein. Levels of p27 were analyzed to ensure uniform loading of the gel. (f) Expression of
the wt and transgene Gfi1b-alleles was detected by RT–PCR in two independent BCR/Abl transformed B-cell lines (1 and 2) before and after HindIII digestion.
EndogenousGfi1b mRNA canbe detected in both cell lines derivedfrom wt bone marrowbut is absent in the cell lines establishedfrom bone marrow ofvav-Gfi1b
transgenic mice.
990 Nucleic Acids Research, 2005, Vol. 33, No. 3number of minor signals (Figure 2a), suggesting the existence
of two major and several minor mRNA start sites in the Gﬁ1b
promoter. A closer inspection of the murine Gﬁ1b gene locus
showed the absence of a classical TATA box which is in
agreement with the existence of several mRNA start sites
(Figure 2b). Interestingly, the distal major mRNA start site
could not be detected in bone marrow cells from vav-Gﬁ1b
transgenic mice. The mapping of the more proximal major
start site is in good agreement with the recent description of
the human Gﬁ1b promoter (19) and the 50 end of the mGﬁ1b
cDNA. A comparison of human, rat and murine sequences
showed a high degree of sequence similarity. In particular,
a conservation of the GATA-1 and NF-Y binding sites
described previously to be important for Gﬁ1b regulation
(19) and of the region around the mRNA start site was evident
(Figure2b). Moreover, four DNase I hypersensitive sites could
be mapped using wt splenocytes that overlap signiﬁcantly with
areas that contain Gﬁ1b-binding sites and regions of high
sequence similarity between human, rat and murine loci
(Figure 3a). In addition, a number of putative Gﬁ1/Gﬁ1b-
binding sites containing the ‘AATC’ core (4) were detected
upstream of the ﬁrst exon. In particular, two very closely
spaced putative binding sites with high sequence similarity
to the ideal Gﬁ1/Gﬁ1b-binding site were found directly
upstream of the mRNA start site and were conserved in all
three species (Figures 2b and 3b).
To test whether this tandem Gﬁ1/Gﬁ1B-binding site can be
recognized by Gﬁ1 proteins, we performed electrophoretic
mobility shift analysis. Oligonucleotides containing the putat-
ive tandem binding site from the Gﬁ1b promoter or the ideal
Gﬁ1 binding site (4) were radioactively labeled and reacted
with in vitro translated Myc-tagged Gﬁ1b and Gﬁ1. Using the
tandem binding site as a probe, four protein:DNA complexes
were obtained (Figure 4) that could be almost completely
disrupted in the presence of both unlabeled ideal and tandem
promoteroligonucleotides(Figure4).However,onlycomplex3
could be efﬁciently supershifted with anti-Myc antibodies
although the intensity of the band representing complex 1 was
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-200
mGfi1B     AAATTTCCAG TGGGTTAGAA G-CTT----- CTGTGAAGTT TTGATAAGCA
rGfi1B     AAAATTCCAG TGGGTTAGAA G-CTT----- CTGTGAAGTT TTGATAAGCA
hGfi1B     TTAGAAA-TG AGAATTCGAA GTCTTGTGTC CTGGAAAGTT TTGATAAGCA
Consensus  ..A......G .G..TT.GAA G.CTT..... CTG..AAGTT TTGATAAGCA
GATA
-150
mGfi1B     AATGTGGCTG CACTTTCGCG CTCTGGTCAT TGGCTGACGC TGCAGCCGCC
rGfi1B     AATGTGGCTG CACTCGGGCG CCCTGGTCAT TGGCTGACGC TGCAGCCGCC
hGfi1B     AATACGGCTG AGCTCCCGCG CTCTCTTCAT TGGCTGCTTG TTCA-CCGCC
Consensus  AAT..GGCTG ..CT...GCG C.CT..TCAT TGGCTG.... T.CA.CCGCC
NF-Y
-100
mGfi1B     AGATTTTGAC ACAAATAATC AGATTGAAAA TCAGGGAGGG GAACAGAAGG
rGfi1B     AGATTTTGAC ACAAATAATC AGATTGAAAA TCAGGGAGGG GAACAGTAGA
hGfi1B     AGATTTTGAC ACAAATAATC AGATTGAAAA TCAGGGAGGG GAACAGAAGA
Consensus  AGATTTTGAC ACAAATAATC AGATTGAAAA TCAGGGAGGG GAACAG.AG.
Gfi1b Gfi1b
-50
mGfi1B     GGGGCGGGAA ACACAGAAAC G-----AAAA GGAGAAGTGT CTGTCTGTGC
rGfi1B     GGGG-GGAAA ACACAGAAAC G-----AAAA GGAGAAGTGT CTGTTTGTGC
hGfi1B     GGAAAAACAC ACAGAGAGAC AGAGCAAAAA GGAGAAGTAT CTATTTGTGC
Consensus  GG......A. ACA.AGA.AC ......AAAA GGAGAAGT.T CT.T.TGTGC
+1  extension primer
mGfi1B     AGAGACTCAT AACGTTGACC GAGCCGAGAG CAGTCCCCAG GGACAGTGTG
rGfi1B     AGAGACTCAT AAAGTTGACA GAGCTGAGAG CAGTCAGCGT GGAGGTTCT-
hGfi1B     AAAGAGTCAC ACAGTTGACA GAGTGGAGGC CAGTCCCGAG AGAGGCTTTG
Consensus  A.AGA.TCA. A..GTTGAC. GAG..GAG.. CAGTC..... .GA...T.T.
5`end of cDNA
+51
mGfi1B     GAGG------ TTCGTGGCTC TCGGGCAGAA CTCAGAAGAG GGACAGCTCC
rGfi1B     -CGG------ CTCTCAGGAC TCGGGCAGAA CTCAGGAGAG GGACAGCTCC
hGfi1B     CAGTTCCCAC CTCGGGAAGC TCCGGCAGAA CCCAGGCGAG GGACAGCTCC
Consensus  ..G....... .TC......C TC.GGCAGAA C.CAG..GAG GGACAGCTCC
Figure 2. Start site mapping and characterization of the Gfi1b promoter. (a) Primer extension on bone marrow and spleen cells from wt and Gfi1b transgenic mice.
The primer for the primer extension analysis hybridizes to the sense strand from nucleotides +34 to +13 in the first exon of the Gfi1b gene. Two major start sites
were conserved in bone marrow and spleen of wt mice, marked by arrows. The more distal start could not be observed in bone marrow RNA from Gfi1b transgenic
mice.Noproductswereobservedintheyeastt-RNAcontrol.(b)Analysisofthemouse,ratandhumanGfi1bpromoter.Nucleotidesequencealignmentofthemouse,
humanandratGfi1bcorepromotersequences.Numbersabovethelinesarethenucleotidenumbersstartingwith+1atthe50 endofthemurinecDNA.Homologyof
themouse,ratandhumanGfi1bpromotersequenceswasanalyzedusingtheMultAlininterfacesoftware(31).Markedinboldlettersintheconsensuslinearethecore
sequences of the binding sites for the transcription factors GATA, NF-Y that have been described previously (19) and the tandem Gfi1b-binding site (boxed). The
arrow above the mGfi1b sequence marks the shortest primer extension product found in bone marrow and spleen (see Figure 2a). The arrow under the hGfi1b
sequence marks the previously described mRNA start site for the human Gfi1b (19). Underlined is the most 50 end of the published cDNA for Gfi1b. The long
arrow marks the localization of the primer used for the primer extension experiments.
Nucleic Acids Research, 2005, Vol. 33, No. 3 991also diminished (Figure 4). Since complexes 1, 2 and 4 but
not 3 appear to be affected by treatment with the unrelated
CREB oligo, it is likely that only complex 3 represents the true
Gﬁ1b/DNA complex (Figure 4). Complexes 1–3 could also be
obtained with Gﬁ1 and the tandem promoter sequence
(Figure 4). Competition with ideal and tandem promoter
sites was equally efﬁcient to disrupt these complexes, but
competition with an unrelated oligo revealed that, in contrast
to Gﬁ1b, only complex 2 appeared to be speciﬁc (Figure 4).
With the ideal Gﬁ1 binding site as a probe, only three
complexes (1, 3 and 4) were obtained with Gﬁ1b (Figure 4)
and again only complex 3 was efﬁciently supershifted with
anti-Myc antibodies. All complexes were disrupted with an
ideal competitor sequence (Figure 4). Strikingly, when Gﬁ1b
was bound to the ideal site, competition with the unlabeled
tandem promoter probe was less efﬁcient than with the
unlabeled ideal probe, suggesting that the ideal binding site
offers a more stable binding to Gﬁ1b than the tandem pro-
moter sequence (Figure 4). In the presence of the unrelated
CREB competitor oligo, all three complexes were still pre-
sent, suggesting that complexes 1, 3 and 4 represent speciﬁc
protein:DNA complexes but only complex 3 is recognized by
the anti-Myc antibody, possibly because of the accessibility of
the epitope tag (Figure 4).
Next, we used reporter gene assays to verify that the Gﬁ1b
gene can be repressed by Gﬁ1b itself. DNA fragments cover-
ing twodifferently extending regions 50 of the Gﬁ1b gene were
inserted into the pGL3 basic vector to drive expression of the
luciferase gene (Figure 5a). Transfection into NIH 3T3 cells
along with Gﬁ1b expression vectors demonstrated a repression
of the Gﬁ1b promoter by Gﬁ1b and also by Gﬁ1 (Figure 5b).
Deletion of the SNAG domain abrogated the repression of
all reporter constructs (Figure 5b). In addition, constructs
that allowed the expression of fusion proteins between Gﬁ1b
and the transactivation domain of the herpes simplex virus
protein VP16, transactivated transcription from the distal
Gﬁ1b promoter and this activity was dependent on the pres-
ence ofall zinc-ﬁnger domains (Figure 5c). To testwhether the
obtained ﬁndings reﬂect a bona ﬁde interaction of Gﬁ1b with
its cognate binding site, we deleted both Gﬁ1/Gﬁ1b-binding
sites and one potential third site in the core promoter and used
this mutated form to drive luciferase in a new reporter gene
construct (Figure 6a and b). Clearly, when these sites were
mutated, Gﬁ1b was no longer able to repress transcription
from the Gﬁ1b core promoter (Figure 6b), indicating the
speciﬁcity of the observed repression shown in Figure 5b.
Gfi1b can repress transcription from the Gfi1
promoter in vivo
It has previously been established that the Gﬁ1 gene underlies
an auto-regulatory feedback control and that Gﬁ1 can bind
directly to sites in its own promoter (8,16). Moreover, it has
also been shown that Gﬁ1b can cross-repress the expression of
Gﬁ1 by using the cognate binding sites in the Gﬁ1 promoter
(16). To test whether the vav-Gﬁ1b transgene would be able to
repress transcription from the Gﬁ1 locus in vivo, we generated
combinatorial mutant mice that carry a Gﬁ1:GFP knock-in
allele where the coding region of the GFP is under the control
of the Gﬁ1 promoter (8) and the vav-Gﬁ1b transgene by cross-
breeding. Indeed, CD4
+ or CD8
+ thymocytes from double-
mutant mice showed a clear shift in GFP ﬂuorescence
which not only conﬁrms the previously described cross-
regulation of the Gﬁ1 gene by Gﬁ1b (16) (Figure 7a) but also
demonstrates the functionality of the vav-Gﬁ1b transgene.
However, no such cross-regulation was observed in myeloid
cells from bone marrow that express the surface markers
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Figure 3. Human–mouse sequence homology, DNase I hypersensitive sites
and Gfi1/Gfi1b binding sites overlap around exon 1 of Gfi1b (a) Mapping of
DNase I hypersensitive sites. Nuclei of splenocytes from a wild-type mouse
(C57Bl/6) were isolated and digested with the indicated amountof DNase I for
15 min on ice. After SmaI digestion, the DNA was separated by 0.8% agarose
gelelectrophoresis,transferredtoanylonmembraneandhybridizedwithaPCR
generated 32P-labeled 285 bp probe covering the most 50 end directly down-
stream of the SmaI site. The result was visualized by autoradiography. The
sequences for the primers to generate the probe were SmaUS1, cctgggatcctt-
cagtggcagag;andSmaLS1,gtcctggaactccctctatagaac.Thepositionsofthecore
promoter, exon 1 and exon 2 relative to the 50-SmaI site were indicated.
The detected hypersensitive sites were marked H1–H4. (b) High similarities
(S1–S5) between mouse and human sequences overlap with the mapped
hypersensitive sites (H1–H4), exon 2, the core promoter sequence (prom)
and the regions where putative Gfi1/Gfi1b binding sites (diamonds) reside.
These similarities are even higher as within the non-coding exon 1.
992 Nucleic Acids Research, 2005, Vol. 33, No. 3Mac-1 and Gr-1 (Figure 7a). Reporter gene assays with a
construct containing the luciferase gene under the control of
the Gﬁ1 promoter described before (8) also demonstrated that
Gﬁ1b can repress transcription of Gﬁ1 and that this depends
on the intactness of the SNAG domain and the presence of all
zinc-ﬁnger domains (Figure 7b). When a fusion protein of
Gﬁ1b and the transactivation domain of the herpes simplex
virus VP16 was used for the same reporter gene assays, tran-
scription was found to be activated and this activation was
dependent on the SNAG domain and the DNA-binding zinc-
ﬁnger domains (Figure 7c).
To test whether Gﬁ1b directly occupies binding sites in
the Gﬁ1b and the Gﬁ1 promoter, we used ChIP. B220
+
cells from wt and vav-Gﬁ1b transgenic mice were puriﬁed
and chromatin–DNA complexes were precipitated with anti-
Gﬁ1b antibodies. After reverse cross-linking, primers located
in the Gﬁ1b or Gﬁ1 promoter region were used for the sub-
sequent PCR reaction. Gﬁ1b/DNA complexes could not only
be detected in wt B-cells but also in B-cells from vav-Gﬁ1b
transgenic mice where they were signiﬁcantly enriched
(Figure 8a and b). With primers located in the CD95 gene
locus where no Gﬁ1/Gﬁ1b binding sites exist, no PCR product
could be obtained indicating the speciﬁcity of the reaction
(Figure 8b). These ﬁndings suggest that Gﬁ1b directly occu-
pies sites in both the Gﬁ1b and the Gﬁ1 promoter.
DISCUSSION
Gﬁ1 and Gﬁ1b are similar proteins with functions in hema-
topoiesis, lymphoid development and a differential, cell type
speciﬁc expression pattern. By using a transgenic mouse
model where Gﬁ1b is constitutively expressed in all hema-
topoietic cells, we can show that the Gﬁ1b gene is under
an auto-regulatory feedback control and silences its own
transcription. Results from the analysis of endogenous and
transgenic mRNA levels in vav-Gﬁ1b transgenic mice, in vitro
gel-shift and reporter gene assays strongly support this auto-
regulatorymechanismattheGﬁ1blocus.Moreover,theresults
of ChIP experiments clearly indicated that Gﬁ1b represses its
transcription by binding to its own promoter sequences in vivo.
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Figure 4. Gfi1 and Gfi1b bind to the tandem Gfi1-binding site in vitro. Upper panel: gel-shift analysis was performed using in vitro translated, Myc-tagged
proteinsand
32P-labeleddouble-strandedoligonucleotidesasindicated.Whereindicated,a50-foldexcessofunlabeleddouble-strandedoligonucleotideswasadded
as a competitor to show sequence-specific binding. The anti-Myc antibody (9E10) was used to generate a supershift of specific protein–oligonucleotide complexes
andtodetectthespecificGfi1/Gfi1b-DNAshiftcomplexeslabeled1–4.Onlycomplex3isefficientlysupershiftedbyantibodyadditionandspecificallycompetedby
the Gfi1/Gfi1b promoter- and ideal-oligonucleotides, but not by the unrelated CREB-binding site oligonucleotide. Lower panel: sequence similarity analysis
comparing the tandem Gfi1-binding site and an ideal Gfi1-binding site used for the gel-shift analysis.
Nucleic Acids Research, 2005, Vol. 33, No. 3 993In addition, vav-Gﬁ1b transgenic mice were used to demon-
strate that Gﬁ1b can regulate the expression of Gﬁ1 in vivo,
which supports earlier ﬁndings (16). Hence, the Gﬁ1b gene
locus can be considered as a bona ﬁde target gene of both
Gﬁ1b and Gﬁ1. Along the same line, we can show that Gﬁ1 is
able to repress expression of reporter genes that depend on the
Gﬁ1b promoter. With these data and our present ﬁndings, it
has to be concluded that both Gﬁ1 and Gﬁ1b are controlled
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994 Nucleic Acids Research, 2005, Vol. 33, No. 3by auto-regulatory feedback loops and can repress expression
of each other in a cross-regulatory fashion. In each case, a
transcriptional repression by direct binding of Gﬁ1 or Gﬁ1b
to the respective promoters is very likely to mediate this
regulation.
It remains unclear at this point whether cross-regulation of
Gﬁ1 and Gﬁ1b genes can be generally held responsible for the
mutually exclusive expression of both proteins that is seen
in some hematopoietic lineages or whether other mechanisms
are also involved. Strikingly, our ﬁndings and previously pub-
lished data (16) demonstrate that cross- and auto-repression of
both Gﬁ1 and Gﬁ1b take place in lymphoid cells but is absent
in the myeloid lineage. It is thus unlikely that the speciﬁc
and exclusive expression of Gﬁ1 in granulocytes [(10);
H. Zeng, unpublished data] and of Gﬁ1b in erythroid
precursors (11,14) is mediated by cross-regulation. In contrast,
cross-repression appears the most likely mechanism to assure
the speciﬁc expression pattern in thymic T-cells, where Gﬁ1
expression levels are high and Gﬁ1b is largely absent. Prelim-
inary data suggest upregulation of the Gﬁ1b gene in Gﬁ1-
deﬁcient thymocytes (K. Fiolka and T. Mo ¨ro ¨y, unpublished
data) and support this hypothesis. Other cell types such as pre-
B-cells or HSCs co-express both proteins but the deletion of
Gﬁ1orGﬁ1biseitherwithoutlargeeffectsasinpre-B-cells,or
only the deletion of Gﬁ1 produces a noticeable phenotype as in
HSCs (14,15) and the absence of Gﬁ1b has no effect (15).
Therefore, it is likely that both proteins may have redundant
functions in one cell type and speciﬁc, nonoverlapping tasks in
others. Additional studies with cell type speciﬁc deletions of
the Gﬁ1 or Gﬁ1b gene have to be done to clarify this point.
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996 Nucleic Acids Research, 2005, Vol. 33, No. 3Deletion of Gﬁ1 has profound effects on thymic pre-T-cell
development (7). If Gﬁ1b cross-regulates the expression of
Gﬁ1 as was convincingly demonstrated previously and is
shown here to be the case, forced expression of a transgenic
Gﬁ1b allele in T-cells should lead to a downregulation of Gﬁ1
in pre-T-cells and to a recapitulation of the phenotype seen
inGﬁ1-deﬁcientmice. However,thisisnotthe case inourvav-
Gﬁ1b transgenic mice although robust expression levels of the
Gﬁ1b transgene could be reached both on mRNA and protein
levels. There are two possible explanations for this observa-
tion. Either the expression level of exogenous Gﬁ1b is still not
high enough to completely downregulate Gﬁ1 expression and
the lower level of Gﬁ1 is sufﬁcient to maintain pre-T-cell
development. Or, alternatively, the concomitant expression
of Gﬁ1b takes over the functions of the suppressed Gﬁ1.
The data presented here from combinatorial mutant mice
that harbor both a Gﬁ1b transgene and the Gﬁ1:GFP allele
suggest that the ﬁrst explanation is more probable, because the
downregulation of GFP ﬂuorescence is partial and not com-
plete indicating that Gﬁ1 expression is not fully silenced
in CD4
+ or in CD8
+ cells. Since a complete silencing of the
Gﬁ1:GFP allele was reached with an lck-driven Gﬁ transgene
as reported previously (8), it is thus most likely that a higher
level of Gﬁ1b transgene expression has to be reached to
observe such a complete downregulation for endogenous
Gﬁ1. In addition, it has been reported that an lck promoter
driven Gﬁ1b transgene with a high-level expression of Gﬁ1b
in the thymus is also able to completely repress Gﬁ1 expres-
sion (9). Both ﬁndings would support the conclusion that a
rather high level of Gﬁ1b expression is necessary to com-
pletely silence endogenous Gﬁ1 which is not reached in our
transgenic model.
In contrast to the vav-Gﬁ1b transgenic mice studied here,
phenotypic alterations in thymocyte differentiation were
observedinlck-Gﬁ1btransgenic mice (9), which was probably
due to the higher expression level in these animals. However,
the phenotype in lck-Gﬁ1b transgenic mice is clearly different
from the effects caused by a targeted deletion of the Gﬁ1
gene (7) leaving the question open whether Gﬁ1b can replace
Gﬁ1 or whether different expression levels of Gﬁ1b can
obscure such an effect. Since Gﬁ1 and Gﬁ1b are clearly dif-
ferent proteins, their ability to act as transcriptional repressors
may vary in particular depending on cellular context and cell
type speciﬁc expression and activity level. In addition,
although Gﬁ1 is expressed at a very high level in thymic
pre-T-cells compared with other cells, as for instance early
B-cell precursors or even activated T-cells, the level of expres-
sion varies signiﬁcantly during pre-T-cell development at
mRNA and protein levels (8), which also suggests the exist-
ence of other mechanisms of regulation in addition to cross-
repression and auto-regulation. Other experimental models
have to be designed to clarify the differences and similarities
of Gﬁ1 and Gﬁ1b functions and to solve the question of to
what degree and under what conditions can Gﬁ1 and Gﬁ1b
possess mutually redundant or exclusive roles.
A more obvious difference between Gﬁ1 and Gﬁ1b is
reﬂected by their role in malignant transformation. A weak
oncogenic activityofGﬁ1hasbeen demonstrated intransgenic
mousemodels where constitutive Gﬁ1expressionwastargeted
to the T-cell lineage by the lck promoter (20). However, no
evidence exists so far that such a role can also be ascribed to
Gﬁ1b. Clearly, when tumors that arise in mice after infection
with MoMuLV are analyzed, the Gﬁ1 gene is one of the most
frequently selected target loci where proviral insertions take
place (21–24). Whereas the Gﬁ1 gene has even been originally
discovered as a proviral insertion site (22), the Gﬁ1b gene is
not a common retroviral target selected during lymphomagen-
esis and has been isolated by virtue of sequence homology to
Gﬁ1 (25,26). Whether this reﬂects a lower ability of Gﬁ1b to
contribute to malignant transformation remains to be shown,
but the transgenic mice that were analyzed in this study did
not show any signs of malignant transformation within the ﬁrst
12 months of life. However, after 1 year, splenomegaly and an
uncharacterized type of lympho- or myelo-proliferative dis-
ease developed (Vassen and Mo ¨ro ¨y, unpublished) suggesting
a potential participation of Gﬁ1b in the development of neo-
plastic diseases. Still, only combinatorial mutant mice bearing
the vav-Gﬁ1b transgene and other mutations in oncogenes
or tumor suppressor genes will unequivocally demonstrate
whether or not Gﬁ1b has any oncogenic potential.
Auto-regulation by genetic feedback loops is a common
phenomenon among eukaryotic transcription factors and has
been described for many other examples (27–30). Here the
situation seems to be more complex, since we provide evid-
ence that Gﬁ1b expression is notonlyunder an auto-regulatory
control but also cross-regulates Gﬁ1 expression. Reporter
gene assays also suggest that Gﬁ1 can regulate the Gﬁ1b pro-
moter, and previously published ﬁndings demonstrated auto-
regulation of Gﬁ1 (8,16). With these data, a picture emerges
for a particularly complex lymphoid-speciﬁc regulatory
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Figure 8. Gfi1b binds to the Gfi1 and Gfi1b promoters sequences in vivo.
(a) Cells from spleen of two wild-type mice were isolated and CH-IP was
performed separately using an a-Gfi1b antibody or no antibody as a control.
TheGfi1b-promoterregioncouldbeamplifiedfrom0.01%ofinputDNA(lanes
1and2)orimmunoprecipitatedDNA(lanes3and4)onlyiftheGfi1bantibody
was used for immunoprecipitation, but not without antibody (lanes 5 and 6).
(b) B220
+ cells from spleen of wild-type and vav-Gfi1b transgenic mice were
isolated and ChIP was performed using an a-Gfi1b antibody. The Gfi1b-
promoterregion (Gfi1blocus) and the Gfi1 promoter region(Gfi1locus) could
be amplified from 0.01% of input DNA or immunoprecipitated DNA. For
the Gfi1b locus, two representative experiments are shown. A more prominent
band is observed if cells from vav-Gfi1b transgenic mice were used for ChIP.
As a negative control, primers from the CD95 gene locus were used.
Nucleic Acids Research, 2005, Vol. 33, No. 3 997network that is built around the two Gﬁ1 proteins, suggesting a
ﬁne-tuned mechanismthatensures precisecontrol overmRNA
and protein levels of both Gﬁ1 proteins. Such a complex regu-
lation may benecessary inlymphoidcellssinceGﬁ1 andGﬁ1b
control essential steps during lymphoid development as the
gene knock-out studies have demonstrated in a most impres-
sive way. In addition, Gﬁ1 can be a transforming onco-protein
and contributes signiﬁcantly to the malignant transformation
of lymphocytes when expressed at high levels. Hence, it is
certainly vital for an organism to closely check Gﬁ1 and Gﬁ1b
expression levels to avoid errors in lymphoid differentiation or
a predisposition to lymphoma.
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